With an ageing population in industrialised countries, the number of people affected by Alzheimer’s disease is increasing dramatically. According to the World Health Organisation (WHO), it is estimated that currently 47.5 million people in the world suffer from dementia. Alzheimer’s disease is involved in 60 to 70% of cases. According to WHO, the number of patients could reach 135 million in 2050.
Based in Lille, AlzProtect develops a drug, AZP2006, whose mode of action and effects differ greatly from products that have been developped by the industry for the past 15 years. This drug acts on main causes of neurodegenerative diseases, and in particular those of Alzheimer’s disease. It is developed primarily for the treatment of Progressive Supranuclear Palsy (PSP), a rare disease that no treatment can stop or slow down.
The product has been tested in a reference rodent model and has demonstrated the reversal of Alzheimer’s symptoms and neuroprotective efficacy: the mice, after having lost their cognitive abilities at an advanced stage, have recovered all of their memory learning abilities.
AZP2006 has been granted the status of «orphan drug» in Europe (European Medicines Agency) and in the United States (Food and Drug Administration) for the treatment of PSP.
It has been tested on healthy subjects during two Phase 1 clinical trials and demonstrated excellent tolerability with no adverse effects.
Phase 2 studies will be conducted soon on patients with PSP. Its placement on the market for this indication is expected in about ten years. A Temporary Use Permits is expected within 3 to 5 years.
ABD, having acquired a unique expertise in the field of cancer, is developing a new cancer treatment therapy. This program, known as SEFALDIN, has proven that it is possible to achieve targeted destruction of cancer cells by restoring the mechanisms for apoptosis that they have escaped by becoming malignant. The originality of the synthetic compound developed by ABD (Dimate) resides in its action on the detoxification mechanisms present in cancer cells.
The first cancer model chosen for this project is acute myeloid leukemia (AML), one of the most challenging cancers. In vitro studies have also validated Dimate’s therapeutic efficacy on aggressive solid tumor models (more than 230 to date) and particularly on resistant lines such as triple negative breast cancer and lung cancer.
Proof of concept has been extended in animal models for AML, melanoma and lung cancer and is in the process of validation for lymphoma, osteosarcoma, breast, pancreatic and colon cancer models
ABD has refined an original method of early diagnosis of sepsis, that has the advantage of being able to detect early signs of the illness even before symptoms appear. This will make it possible to treat potentially severe infections more expediently and therefore to significantly reduce mortality associated with the absence of such early diagnosis (leading cause of death in intensive care units). This kit is in the validation phase and being adapted to hospital routine in partnership with the public hospital system (AP-HP) of Paris for a planned market launch in 2017.
Biolog-id’s product line combines specific hardware and software designed by Biolog-id, RFID (Radio Frequency Identification) labels and the know-how of integrators specialized in the healthcare sector.
Biolog® solutions are geared towards all operators in the «blood» sector: transfusion centers, hospitals and clinics, and the plasma fractionation industry.
Biolog-id is currently transposing this system for use in the injectable chemotherapy sector.
XERYS FRANCE
7 rue d’Aguesseau
75008 Paris - France
+33 (0)1 82 52 12 25
